Skip to content
Canadian orders above $200 ship free · Dispatched from Canadian stock

Buy GLOW peptide stack in Canada

GLOW blend in Canada

GLOW blend, offered as a lyophilised powder in 70 mg vials. HPLC tests every batch, and shipping is from Canadian stock. For laboratory research use only.

Format
Size
$95.00$1.36/mg
Dispatched from Canadian stock

Buy more, pay less per vial

Add 2 more to save 4%

Frequently bought together

At a glance
Also known as
GLOW peptide · GLOW blend · GHK-Cu BPC-157 TB-500 blend · GLOW 70 mg · GLOW stack · GLOW peptide stack
Class
Three-peptide research blend joining a copper tripeptide, a gastric pentadecapeptide and a thymosin beta-4 related peptide
Form
Lyophilised powder supplied in 70 mg vials
Sizes
70 mg
Storage, dry
−20 °C, dry and dark
Storage, mixed
2–8 °C, use within 28 days of mixing (as generally reported for reconstituted peptides)
BAC water per size
70 mg: 5 mL

What is GLOW?

GLOW blend comes as a single vial carrying GHK-Cu 50 mg, BPC-157 10 mg and TB-500 10 mg together in one lyophilised powder. The literature studies the components apart from each other, and the references gathered on this page are those separate studies. The recorded sequences are: GHK-Cu, Gly-His-Lys with a copper(II) ion; BPC-157, 15 residues; and the TB-500 literature, which studies thymosin beta-4, a 43-residue peptide. The published research spans rat, human, mouse and cell-culture work. One of the 8 studies listed below is a controlled trial in people. We supply it as a lyophilised powder in 70 mg vials from Canadian stock, for laboratory research. It is no medicine and is not for use in humans or animals.

What the research shows

StudyModelDose usedDurationFinding
Miller TR et al.2006 · Arch Facial Plast Surg · PMID 16847171Human, randomised controlled trial (n=13 completed), skin after CO2 laser resurfacingTopical skin care products with or without GHK-Cu; concentration not stated in the abstract12 weeksComputer analysis and blinded evaluators found no significant difference between groups in erythema, wrinkles or overall skin quality. On the patient questionnaire, rated improvement in overall skin quality was higher in the GHK-Cu group (P = .04).
Lee E et al.2024 · Altern Ther Health Med · PMID 39325560Human, uncontrolled pilot study (n=12 women with interstitial cystitis), private clinic10 mg total, given by injection around the inflamed area of the bladder during cystoscopySingle procedure; follow-up period not stated in the abstractTen of 12 patients reported complete resolution of symptoms and 2 of 12 rated their success at 80%. No adverse events were reported. The study had no control group.
Pollard JD et al.2005 · Arch Facial Plast Surg · PMID 15655171Cell culture (normal and irradiated human dermal fibroblasts)1 × 10⁻⁹ mol/LNot stated in the abstractGHK-Cu shortened the population-doubling time of normal and irradiated fibroblasts. Treated irradiated fibroblasts produced significantly more basic FGF and VEGF than untreated controls early after exposure.
Wang X et al.2017 · Wound Repair Regen · PMID 28370978Mouse, scald burn model; human umbilical vein endothelial cells (HUVECs)GHK-Cu in liposomes; amount not stated in the abstractWound healing time 14 days post injury in the liposome groupGHK-Cu liposomes raised HUVEC proliferation by 33.1% and gave better angiogenesis in burned skin than free GHK-Cu, with wound healing time shortened to 14 days.
Deng M et al.2023 · J Cachexia Sarcopenia Muscle · PMID 36905132Mouse (C57BL/6), cigarette-smoke muscle dysfunction model; C2C12 muscle cells; plasma GHK measured in people with COPD (n=9) and healthy controls (n=11)0.2 and 2 mg/kg (route not stated in the abstract)Not stated in the abstractGHK-Cu reduced smoke-induced loss of muscle mass and improved grip strength (175.5 g untreated vs 257.6 g and 339.1 g). Plasma GHK was lower in the COPD group than in controls.
Duzel A et al.2017 · World J Gastroenterol · PMID 29358856Rat, ischaemic colitis and reperfusion model10 μg/kg as a bath (1 mL/rat) on the blood-deprived colon segment15 min vessel recording; day 10 in the colon obstruction groupBPC-157 increased vessel presentation and collateral connections, and MDA and NO levels were normal in treated rats. On day 10 the obstructed segments showed almost completely spared mucosa.
Maar K et al.2025 · Int J Mol Sci · PMID 40362372Mouse, permanent coronary ligation (heart attack) model; human cardiac cellsSystemic TB4 injection; amount not stated in the abstractNot stated in the abstractTB4 raised miR139-5p expression and modulated ROCK1 protein levels in mouse hearts and human cardiac cells, and may reverse or inhibit fibroblast-to-myofibroblast transformation.
Bako P et al.2023 · Int Immunopharmacol · PMID 38706788Mouse tympanic membrane (eardrum) explants, ex vivo and on collagen gelsNot stated in the abstractNot stated in the abstractTB4 affected the migration and proliferation of epidermal and epithelial cells of the tympanic membrane in vitro, most likely acting on local epidermal progenitor cells.

What these studies don't show: The controlled evidence is genuine but tied to one particular setting. Trial populations are hand-picked, endpoints are frequently surrogate measures rather than outcomes, and follow-up seldom runs long. Safety beyond those trial conditions stays unestablished. The HPLC trace shows content, which is a question apart from efficacy.

Every study links to its PubMed record. See all GLOW studies in the research library →

GLOW price in Canada: 70mg vial

Buy GLOW peptide stack in Canada in a 70mg vial and a starter kit. Prices are in Canadian dollars, you pay by Interac e-Transfer or bank transfer, and orders are shipped from Canadian stock.

SizePricePer mg
70 mg$95.00$1.36/mg

Starter kit

Is GLOW available in Canada?

No GLOW blend product is authorized in Canada; no DIN has ever been issued for it. That means Health Canada has not assessed it for safety, efficacy or quality. This is laboratory research material in our hands, not for use in a person or an animal. How Health Canada treats research peptides →

Side effects reported in studies

Every statement is pinned to the study that made it. Any tolerability finding below is quoted straight from the study that reported it. Human work on this scale cannot build a safety profile. Read more →

Doses used in studies

Read more →

GLOW FAQ

What is GLOW blend?

GLOW blend is a three-peptide research blend: a copper tripeptide, a gastric pentadecapeptide and a thymosin beta-4 related peptide, and that classification is where the published work begins. The published research covers rat, human, mouse and cell-culture work. Borealis Peptides offers it as a lyophilised powder in 70 mg vials for in-vitro laboratory research. It holds no medicinal authorization and is not for use in any living subject. Each reference here appears alongside the model it ran in and the result as it was published.

Where can I buy GLOW blend in Canada?

Straight from Borealis Peptides, kept in Canadian stock so nothing has to clear a border to reach you. Held in 70 mg vials. Purity is verified by HPLC batch by batch, and we supply for laboratory research only. Identity and purity are checked per batch, and the paperwork names that batch specifically.

Is GLOW blend legal in Canada?

No GLOW blend product is authorized in Canada; no DIN has ever been issued for it. That means Health Canada has not assessed it for safety, efficacy or quality. We hold it purely as laboratory research material, not for use in any person or animal. Health Canada has stated that "Research Use Only" labelling does not make a product legal to use in a person, so we take it as a note on the intended supply and not as leave to use the material.

How much GLOW blend should I use?

We take no dosing questions. GLOW blend is not supplied for use in a person or an animal, so there is no dose to set out. What this page carries is the amount each cited study used and the model it used it in, reproduced as the authors published it.

What human evidence is there for GLOW blend?

Of the 8 studies cited, one is a controlled trial in people and the others are animal or cell work. Each row names its model, the amount used and what the authors reported, so the weight of each study can be judged directly rather than through a summary.

What storage does GLOW blend need?

Keep sealed vials at −20 °C, dry and shielded from light. After reconstitution, 2–8 °C. Since the dry form is stable at room temperature, shipping calls for no cold chain; refrigerate it on arrival. Light and repeated warming harm it more than the trip itself.

How is the purity of GLOW blend confirmed?

HPLC tests each batch before it is sold, and the certificate points to the batch in your vial rather than to the product at large. Filing that batch number with your records is what lets an observation be reproduced later. Certificates are available on request.

How does GLOW blend compare with GHK-Cu and KLOW?

Each carries its own published record, and comparing them comes down to reading both. GHK-Cu and KLOW have 8 cited studies and 8 cited studies on their page against 8 here. What sets them apart is the published work, which both pages lay out in full.

Why is GLOW blend named in a Health Canada advisory?

Because it was one of the peptides seized from sellers putting unauthorized injectable products online. The advisory addresses material sold for people to inject without authorization. The material Borealis Peptides provides is for in-vitro laboratory research alone, with nothing sold for injection or for any use in a person, which is the very separation the advisory is built around.

Compare with